{"success":true,"data":{"pressRelease":{"id":"4691","rtpr_id":"nGNX1S9XXQ","ticker":"MBOT","exchange":"NASDAQ","all_tickers":["MBOT"],"title":"Microbot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®","author":"Globe Newswire","published_at":"2026-04-22T12:30:00.340Z","article_body":"Members of the Society of Interventional Radiology (SIR) and the\nCardiovascular and Interventional Radiological Society of Europe (CIRSE)\nRepresent the Largest Addressable User Market for the LIBERTY System\n\nAt least Nine Medical Societies Endorse Updated Guidelines to Lower Radiation\nExposure and Improve Ergonomic Issues Impacting Health Practitioners\n\nHINGHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc.\n(Nasdaq: MBOT), developer and distributor of the innovative LIBERTY(®)\nEndovascular Robotic System, today highlighted that the Society of\nInterventional Radiology (SIR) and the Cardiovascular and Interventional\nRadiological Society of Europe (CIRSE), recently released updated joint\nguidelines on occupational protection in interventional radiology. The revised\nguideline provides important safety guidance to physicians, radiographers,\nnurses, medical physics experts, and all other staff involved in\ninterventional radiology procedures.\n\nThe guidelines, which were published in CardioVascular and Interventional\nRadiology (CVIR), cover updated clinical evidence, new exposure sources and\naddress musculoskeletal risks for interventional radiology staff and, for the\nfirst time, include a section on radiation protection during pregnancy for\nfemale practitioners.\n\n“Part of our mission for the LIBERTY System is to enable physicians to\ncontinue improving and saving patients’ lives while protecting their own.\nLIBERTY’s design aims to reduce radiation exposure and physical strain for\nphysicians and related medical staff, positioning the LIBERTY System as a\npotential solution to address both the health, and the staffing challenges in\ninterventional care,” commented Harel Gadot, Chairman, CEO & President.\n“It is very encouraging to see increased emphasis on protecting healthcare\nproviders in the interventional space coming from leading medical societies,\nsuch as the American Medical Association (AMA), one of the largest medical\nassociations in the U.S., along with SIR and CIRSE.”\n\nProlonged exposure to radiation may have significant long-term health risks,\nincluding cancer, cardiovascular disease, reproductive health effects, and\ncataracts. These risks have also been cited as contributing to the staffing\nshortage in the endovascular space, especially in interventional radiology,\nwhich currently ranks number two among specialties with highest physician\nshortages. The burden disproportionately affects women, who often cite\nradiation exposure and the physical demands of wearing lead aprons as barriers\nto entering or advancing in the field. The LIBERTY System’s remote operation\ncapabilities enable physicians to work away from the radiation source and in a\nseated position, potentially lowering musculoskeletal strain while improving\nworkflow efficiency.\n\nAlong with SIR and CIRSE, occupational protection initiatives are being\nendorsed by the Society of NeuroInterventional Surgery (SNIS), the Society of\nVascular and Interventional Neurology (SVIN), the Society for Cardiovascular\nAngiography and Interventions (SCAI), American College of Cardiology (ACC),\nthe Alliance for Cardiovascular Professionals (ACVP), the American Society of\nEchocardiography (ASE), the Heart Rhythm Society (HRS), and Society for\nVascular Surgery (SVS). Additionally, in late 2025, the American Medical\nAssociation (AMA) adopted a new policy to strengthen protections for\nhealthcare professionals and trainees who may face occupational radiation\nexposure. The policy emphasizes the importance of continued research into the\nhealth effects of cumulative exposure to ionizing radiation, as well as\neducation and training to minimize occupational risk to physicians and\npatients.\n\nAbout Microbot Medical\n\nMicrobot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device\ncompany focused on transforming endovascular procedures through advanced\nrobotic technology. Microbot’s LIBERTY(®) Endovascular Robotic System is\nthe world’s first FDA cleared single-use, remotely operated robotic solution\ndesigned for precision, efficiency and safety. Backed by a strong intellectual\nproperty portfolio and a commitment to innovation, Microbot is driving the\nfuture of endovascular care.\n\nLearn more at www.microbotmedical.com and connect on LinkedIn\n(https://www.globenewswire.com/Tracker?data=7E_LCPbTsVlyKbYlAlrMVnGgPwcsngyW9o4mrUO_NKmpy0pLRzz0s40OZDPLyOyxXiPKI5eatQDWKzUy5fH5BBf8vkYthMGktO_ADzo9VPZAc3hQQchwPsD5NaRD_43U)\nand X\n(https://www.globenewswire.com/Tracker?data=SMbHzbuQq2MpwTnEYZZygIWLiHisBaGdm47wjmdFXhQg39rZH_suWqYyAdJ2RyrWmF49zKSbyFWBb4nOfoMLSA==).\n\nSafe Harbor\n\nStatements to future financial and/or operating results, future adoption of\nproducts, future growth in research, technology, clinical development,\ncommercialization and potential opportunities for Microbot Medical Inc. and\nits subsidiaries, along with other statements about the future expectations,\nbeliefs, goals, plans, or prospects expressed by management, constitute\nforward-looking statements within the meaning of the Private Securities\nLitigation Reform Act of 1995 and the Federal securities laws. Any statements\nthat are not historical fact (including, but not limited to statements that\ncontain words such as “contemplates,” “continues,” “could,”\n“forecasts,” “intends,” “may,” “might,” “possible,”\n“potential,” “predicts,” “projects,” “should,” “would,”\n“will,” “believes,” “plans,” “anticipates,” “expects,”\n“estimates” and similar expressions) should also be considered to be\nforward-looking statements, but the absence of these words does not mean that\na statement is not forward-looking. Forward-looking statements involve risks\nand uncertainties, including, without limitation, market conditions, risks\ninherent in the commercialization of the LIBERTY(®) Endovascular Robotic\nSystem, and in the development of future versions of or applications for the\nsystem, uncertainty in the results of regulatory pathways and regulatory\napprovals, uncertainty resulting from political, social and geopolitical\nconditions, particularly any changes in personnel or processes or procedures\nat the FDA and announcements of tariffs on imports into the U.S., disruptions\nresulting from new and ongoing hostilities between Israel and the\nPalestinians, Iran and other neighboring countries, and maintenance of\nintellectual property rights. Additional information on risks facing Microbot\nMedical(®) can be found under the heading “Risk Factors” in Microbot\nMedical’s periodic reports filed with the Securities and Exchange Commission\n(SEC), which are available on the SEC’s web site at www.sec.gov. Microbot\nMedical(®) disclaims any intent or obligation to update these forward-looking\nstatements, except as required by law.\n\nContacts: \nIR@microbotmedical.com\nMedia@microbotmedical.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/346df7fb-c134-40c2-970a-39bcbaf974cd)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1S9XXQ","title":"Microbot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®","author":"Globe Newswire","ticker":"MBOT","created":"2026-04-22T12:30:00.340Z","tickers":["MBOT"],"exchange":"NASDAQ","article_body":"Members of the Society of Interventional Radiology (SIR) and the\nCardiovascular and Interventional Radiological Society of Europe (CIRSE)\nRepresent the Largest Addressable User Market for the LIBERTY System\n\nAt least Nine Medical Societies Endorse Updated Guidelines to Lower Radiation\nExposure and Improve Ergonomic Issues Impacting Health Practitioners\n\nHINGHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc.\n(Nasdaq: MBOT), developer and distributor of the innovative LIBERTY(®)\nEndovascular Robotic System, today highlighted that the Society of\nInterventional Radiology (SIR) and the Cardiovascular and Interventional\nRadiological Society of Europe (CIRSE), recently released updated joint\nguidelines on occupational protection in interventional radiology. The revised\nguideline provides important safety guidance to physicians, radiographers,\nnurses, medical physics experts, and all other staff involved in\ninterventional radiology procedures.\n\nThe guidelines, which were published in CardioVascular and Interventional\nRadiology (CVIR), cover updated clinical evidence, new exposure sources and\naddress musculoskeletal risks for interventional radiology staff and, for the\nfirst time, include a section on radiation protection during pregnancy for\nfemale practitioners.\n\n“Part of our mission for the LIBERTY System is to enable physicians to\ncontinue improving and saving patients’ lives while protecting their own.\nLIBERTY’s design aims to reduce radiation exposure and physical strain for\nphysicians and related medical staff, positioning the LIBERTY System as a\npotential solution to address both the health, and the staffing challenges in\ninterventional care,” commented Harel Gadot, Chairman, CEO & President.\n“It is very encouraging to see increased emphasis on protecting healthcare\nproviders in the interventional space coming from leading medical societies,\nsuch as the American Medical Association (AMA), one of the largest medical\nassociations in the U.S., along with SIR and CIRSE.”\n\nProlonged exposure to radiation may have significant long-term health risks,\nincluding cancer, cardiovascular disease, reproductive health effects, and\ncataracts. These risks have also been cited as contributing to the staffing\nshortage in the endovascular space, especially in interventional radiology,\nwhich currently ranks number two among specialties with highest physician\nshortages. The burden disproportionately affects women, who often cite\nradiation exposure and the physical demands of wearing lead aprons as barriers\nto entering or advancing in the field. The LIBERTY System’s remote operation\ncapabilities enable physicians to work away from the radiation source and in a\nseated position, potentially lowering musculoskeletal strain while improving\nworkflow efficiency.\n\nAlong with SIR and CIRSE, occupational protection initiatives are being\nendorsed by the Society of NeuroInterventional Surgery (SNIS), the Society of\nVascular and Interventional Neurology (SVIN), the Society for Cardiovascular\nAngiography and Interventions (SCAI), American College of Cardiology (ACC),\nthe Alliance for Cardiovascular Professionals (ACVP), the American Society of\nEchocardiography (ASE), the Heart Rhythm Society (HRS), and Society for\nVascular Surgery (SVS). Additionally, in late 2025, the American Medical\nAssociation (AMA) adopted a new policy to strengthen protections for\nhealthcare professionals and trainees who may face occupational radiation\nexposure. The policy emphasizes the importance of continued research into the\nhealth effects of cumulative exposure to ionizing radiation, as well as\neducation and training to minimize occupational risk to physicians and\npatients.\n\nAbout Microbot Medical\n\nMicrobot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device\ncompany focused on transforming endovascular procedures through advanced\nrobotic technology. Microbot’s LIBERTY(®) Endovascular Robotic System is\nthe world’s first FDA cleared single-use, remotely operated robotic solution\ndesigned for precision, efficiency and safety. Backed by a strong intellectual\nproperty portfolio and a commitment to innovation, Microbot is driving the\nfuture of endovascular care.\n\nLearn more at www.microbotmedical.com and connect on LinkedIn\n(https://www.globenewswire.com/Tracker?data=7E_LCPbTsVlyKbYlAlrMVnGgPwcsngyW9o4mrUO_NKmpy0pLRzz0s40OZDPLyOyxXiPKI5eatQDWKzUy5fH5BBf8vkYthMGktO_ADzo9VPZAc3hQQchwPsD5NaRD_43U)\nand X\n(https://www.globenewswire.com/Tracker?data=SMbHzbuQq2MpwTnEYZZygIWLiHisBaGdm47wjmdFXhQg39rZH_suWqYyAdJ2RyrWmF49zKSbyFWBb4nOfoMLSA==).\n\nSafe Harbor\n\nStatements to future financial and/or operating results, future adoption of\nproducts, future growth in research, technology, clinical development,\ncommercialization and potential opportunities for Microbot Medical Inc. and\nits subsidiaries, along with other statements about the future expectations,\nbeliefs, goals, plans, or prospects expressed by management, constitute\nforward-looking statements within the meaning of the Private Securities\nLitigation Reform Act of 1995 and the Federal securities laws. Any statements\nthat are not historical fact (including, but not limited to statements that\ncontain words such as “contemplates,” “continues,” “could,”\n“forecasts,” “intends,” “may,” “might,” “possible,”\n“potential,” “predicts,” “projects,” “should,” “would,”\n“will,” “believes,” “plans,” “anticipates,” “expects,”\n“estimates” and similar expressions) should also be considered to be\nforward-looking statements, but the absence of these words does not mean that\na statement is not forward-looking. Forward-looking statements involve risks\nand uncertainties, including, without limitation, market conditions, risks\ninherent in the commercialization of the LIBERTY(®) Endovascular Robotic\nSystem, and in the development of future versions of or applications for the\nsystem, uncertainty in the results of regulatory pathways and regulatory\napprovals, uncertainty resulting from political, social and geopolitical\nconditions, particularly any changes in personnel or processes or procedures\nat the FDA and announcements of tariffs on imports into the U.S., disruptions\nresulting from new and ongoing hostilities between Israel and the\nPalestinians, Iran and other neighboring countries, and maintenance of\nintellectual property rights. Additional information on risks facing Microbot\nMedical(®) can be found under the heading “Risk Factors” in Microbot\nMedical’s periodic reports filed with the Securities and Exchange Commission\n(SEC), which are available on the SEC’s web site at www.sec.gov. Microbot\nMedical(®) disclaims any intent or obligation to update these forward-looking\nstatements, except as required by law.\n\nContacts: \nIR@microbotmedical.com\nMedia@microbotmedical.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/346df7fb-c134-40c2-970a-39bcbaf974cd)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-22T12:30:00.611277959Z","server_sent_at_ms":1776861000611},"received_at":"2026-04-22T12:30:00.675Z","source_url":null},"analysis":{"id":"3313","press_release_id":"4691","analysis_json":{"industry":{"label":"Health Care Equipment & Services","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Microbot Medical highlighted updated occupational protection guidelines from SIR and CIRSE, which address radiation exposure and ergonomic risks for interventional radiology staff.\n\nThe company positions its LIBERTY robotic system as a solution to these specific challenges, noting that remote operation capabilities reduce physical strain and radiation exposure for physicians.\n\nAt least nine medical societies, including the AMA, have endorsed initiatives to strengthen protections, reinforcing the commercial relevance of safety-focused technology.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Major medical societies endorse safety guidelines that align directly with LIBERTY's value proposition."},"keyFigures":{},"quotedText":"Part of our mission for the LIBERTY System is to enable physicians to continue improving and saving patients’ lives while protecting their own.","namedEntities":{"people":[{"name":"Harel Gadot","role":"Chairman, CEO & President"}],"products":["LIBERTY Endovascular Robotic System"],"companies":[{"name":"Society of Interventional Radiology","relationship":"industry organization"},{"name":"Cardiovascular and Interventional Radiological Society of Europe","relationship":"industry organization"},{"name":"American Medical Association","relationship":"industry organization"},{"name":"Microbot Medical Inc.","ticker":"MBOT"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"The release highlights external industry guidelines that align with the company's value proposition, providing a supportive narrative for sales. However, it lacks specific financial data, contractual wins, or regulatory milestones that typically drive immediate stock price movements."},"tickerRelevance":{"others":[],"primary":"MBOT"},"eventTypeSecondary":[]},"event_type":"other","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Microbot Medical highlighted updated occupational protection guidelines from SIR and CIRSE, which address radiation exposure and ergonomic risks for interventional radiology staff.\n\nThe company positions its LIBERTY robotic system as a solution to these specific challenges, noting that remote operation capabilities reduce physical strain and radiation exposure for physicians.\n\nAt least nine medical societies, including the AMA, have endorsed initiatives to strengthen protections, reinforcing the commercial relevance of safety-focused technology.","key_figures":{},"named_entities":{"people":[{"name":"Harel Gadot","role":"Chairman, CEO & President"}],"products":["LIBERTY Endovascular Robotic System"],"companies":[{"name":"Society of Interventional Radiology","relationship":"industry organization"},{"name":"Cardiovascular and Interventional Radiological Society of Europe","relationship":"industry organization"},{"name":"American Medical Association","relationship":"industry organization"},{"name":"Microbot Medical Inc.","ticker":"MBOT"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-22T15:54:59.481Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:54.160Z"}},"durationMs":102749,"modelName":"glm-4.7"}}